![]() |
|
|
Department of Pharmaceutics, University of Washington (J.T.S.,
J.Y.C., K.E.T.) and
Fred Hutchinson Cancer Research Center (J.T.S.)
Models of the time course of the effect of P450 induction on
substrate clearance have previously only considered induction through
enhanced synthesis of protein. Induction of CYP2E1 does not always
conform to this model, in that many chemicals induce the enzyme through
stabilization of the protein apparently by binding to the active site.
While such binding protects the enzyme from degradation, it also
results in competitive inhibition of substrate clearance. We present a
model based on experimental studies of chemical induction of CYP2E1 by
ligand stabilization through which this mechanism of induction can be
translated into its pharmacokinetic consequence with regard to
clearance of substrate. CYP2E1 is considered to be localized in two
pools: Pool 1 at which two mechanisms of degradation, fast and slow,
operate and pool 2, at which only the slower mechanism operates.
Binding of substrate to enzyme in pool 1 stabilizes it from degradation
by the fast process, leaving only the slow process. Ligand
stabilization therefore results in induction of CYP2E1 as enzyme
accumulates as a consequence of unchanged synthesis. Binding of ligand
to the active site results in competitive inhibition of the clearance
of substrate. Model-based computer simulations show that the time
course of interaction between inhibitor/inducer and substrate can be
predicted from knowledge of I/Ki and
S/Km and the synthesis and degradation kinetics of CYP2E1. The simulations demonstrate further that as long as inhibitor/inducer administration is not interrupted, the clearance of
substrate will always be less than the value observed at low concentration of substrate even if the substrate concentration is
raised to displace inhibitor/inducer from the active site. On the other
hand, the degree of inhibition of clearance is less than would be seen
if induction had not taken place. Clearance of substrate is observed to
rise above the value observed in the absence of the inhibitor/inducer
only after the inhibitor/inducer concentration declines low enough for
substrate to gain access to the active site of the enzyme. The
model-based simulations agree with reports of the interaction between
isoniazid and acetaminophen in humans.
This article has been cited by other articles:
![]() |
J. S. Lee, W. O. Ward, D. C. Wolf, J. W. Allen, C. Mills, M. J. DeVito, and J. C. Corton Coordinated Changes in Xenobiotic Metabolizing Enzyme Gene Expression in Aging Male Rats Toxicol. Sci., November 1, 2008; 106(1): 263 - 283. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. E Schwab and H. Tuschl In vitro studies on the toxicity of isoniazid in different cell lines Human and Experimental Toxicology, November 1, 2003; 22(11): 607 - 615. [Abstract] [PDF] |
||||
![]() |
A. Madan, R. A. Graham, K. M. Carroll, D. R. Mudra, L. A. Burton, L. A. Krueger, A. D. Downey, M. Czerwinski, J. Forster, M. D. Ribadeneira, et al. Effects of Prototypical Microsomal Enzyme Inducers on Cytochrome P450 Expression in Cultured Human Hepatocytes Drug Metab. Dispos., April 1, 2003; 31(4): 421 - 431. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Zhao and J. T. Slattery Effects of Ethanol Dose and Ethanol Withdrawal on Rat Liver Mitochondrial Glutathione: Implication of Potentiated Acetaminophen Toxicity in Alcoholics Drug Metab. Dispos., December 1, 2002; 30(12): 1413 - 1417. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Desta, N. V. Soukhova, and D. A. Flockhart Inhibition of Cytochrome P450 (CYP450) Isoforms by Isoniazid: Potent Inhibition of CYP2C19 and CYP3A Antimicrob. Agents Chemother., February 1, 2001; 45(2): 382 - 392. [Abstract] [Full Text] |
||||
![]() |
B. S. Mayhew, D. R. Jones, and S. D. Hall An In Vitro Model for Predicting In Vivo Inhibition of Cytochrome P450 3A4 by Metabolic Intermediate Complex Formation Drug Metab. Dispos., September 1, 2000; 28(9): 1031 - 1037. [Abstract] [Full Text] |
||||
![]() |
M. G. Emery, C. Jubert, K. E. Thummel, and E. D. Kharasch Duration of Cytochrome P-450 2E1 (CYP2E1) Inhibition and Estimation of Functional CYP2E1 Enzyme Half-Life after Single-Dose Disulfiram Administration in Humans J. Pharmacol. Exp. Ther., October 1, 1999; 291(1): 213 - 219. [Abstract] [Full Text] |
||||